Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Multiple myeloma is a cancer that affects plasma cells, a type of white blood cell in your bone marrow. Although treatments have improved, myeloma often comes back after an initial response. This Phase 3 clinical trial is testing a new drug called cevostamab. Participants will either receive cevostamab combined with two established drugs (pomalidomide and dexamethasone) or one of several current standard treatments. Cevostamab is designed to help your own immune system find and attack cancer cells. This trial is for adults aged 18 and over who have already had between one and three previous treatments for myeloma that have stopped working. Researchers will compare how well both approaches keep the cancer under control and what side effects they cause. Taking part helps doctors learn if this new combination could become a better treatment option in the future.
At a glance
What is this study about?
Multiple myeloma develops inside the bone marrow, the spongy centre of bones where blood cells are made. Over time, myeloma cells crowd out healthy blood cells, which can cause bone pain, fatigue, and frequent infections. While treatments can control the cancer for long periods, it often returns or stops responding to familiar medicines. When this happens, doctors need new and effective options.
This trial investigates an experimental medicine called cevostamab. Cevostamab is a type of immunotherapy. It acts like a bridge, bringing your body's natural infection-fighting T-cells directly to the myeloma cells to destroy them. In this study, cevostamab is given alongside pomalidomide and dexamethasone, which are medicines already widely used to treat myeloma.
Researchers are comparing this new three-drug combination against the current standard treatments used in hospitals today. Because this is a Phase 3 trial, it is one of the final stages of research needed to prove whether a new treatment is truly better and safe enough to be approved for wider use.
Finding treatments that can restart the immune response against myeloma is vital. If successful, this study could give people whose cancer has returned a powerful new choice to keep their disease in check for longer.
Key takeaways
- Tests a new immunotherapy drug called cevostamab combined with standard medicines.
- Aimed at adults with multiple myeloma that has come back after 1 to 3 previous treatments.
- Compares the new combination against current standard treatment options.
- Involves regular clinic visits for drips, tablets, blood tests, and scans.
- Participation is completely voluntary and you can withdraw at any time.
Who may be eligible?
You may be able to join this trial if you are 18 or older and have been diagnosed with multiple myeloma that is measurable through standard blood or urine tests. You must have already tried between one and three previous treatment courses, and these must have included specific common medicines known as lenalidomide and an anti-CD38 drug.
You should be well enough to carry out most daily activities, although people with reduced mobility caused purely by myeloma-related bone pain may still be eligible. Your specialist will review your overall fitness to ensure taking part is safe for you.
You will not be able to join if your cancer has spread to your brain or nervous system, or if you have certain other conditions such as plasma cell leukaemia or severe amyloidosis affecting major organs. People with digestive conditions that stop tablets being properly absorbed into the body are also unable to take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or over.
- I have been diagnosed with multiple myeloma.
- I have already received between 1 and 3 lines of treatment for my myeloma.
- My past treatments included lenalidomide and an anti-CD38 medicine.
- I am generally active enough to look after myself day-to-day.
What does participation involve?
If you take part, you will be placed by chance (like flipping a coin) into one of two groups. One group receives the new drug cevostamab along with pomalidomide and dexamethasone. The other group receives an existing standard treatment chosen by your doctor. Cevostamab is given through a drip into a vein, while other study medicines are taken as tablets or injections. You will have regular hospital visits for check-ups, blood tests, and scans to see how your body is responding. Treatment continues for as long as it is working and side effects remain manageable. After stopping the medication, your care team will continue to check on your health periodically.
Potential risks and benefits
Locations (105)
- City of Hope National Medical CenterVerified postcodeDuarte, United States· Recruiting
- City of Hope - Lennar Foundation Cancer CenterVerified postcodeIrvine, United States· Recruiting
- Yale UniversityVerified postcodeNew Haven, United States· Recruiting
- MedStar Washington Hospital Center MedStar Georgetown Cancer InstituteVerified postcodeWashington D.C., United States· Recruiting
- Emory University Hospital MidtownVerified postcodeAtlanta, United States· Recruiting
- University of IllinoisVerified postcodeChicago, United States· Recruiting
- Novant Health Cancer InstituteVerified postcodeCharlotte, United States· Recruiting
- Forsythe Memorial Hospital Inc., dba Novant Health Oncology SpecialistsVerified postcodeWinston-Salem, United States· Recruiting
- TriHealth Cancer and Blood InstituteVerified postcodeCincinnati, United States· Recruiting
- Perelman Center for Advanced MedicineVerified postcodePhiladelphia, United States· Recruiting
- MD Anderson Cancer CenterVerified postcodeHouston, United States· Recruiting
- Texas Tech University Health Sciences CenterVerified postcodeLubbock, United States· Recruiting
Common questions
Will I definitely receive the new drug cevostamab?
Not necessarily. This is a randomised trial, which means a computer assigns you to either the new drug combination or a proven standard treatment. This ensures the comparison is fair.
What is a Phase 3 trial?
A Phase 3 trial is a large study that tests whether a new treatment works better, or has fewer side effects, than the best treatments currently available.
How long will I be in the trial?
You will usually stay on the study treatment for as long as it keeps your cancer under control and you are not troubled by serious side effects. Your team will monitor you for months or years afterwards.
Will taking part cost me anything?
No. The study medicines and extra tests are provided free of charge, though you should check with the hospital team whether travel expenses can be reimbursed.
What happens if my cancer gets worse during the trial?
Your doctor will check your cancer regularly. If the treatment stops working, you will stop the trial medicine, and your doctor will discuss other treatment options with you immediately.
How to find out more
Reference Study ID Number: CO46096 https://forpatients.roche.com/ No attachments to email below.
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.